Identification of risk factors and development of a predictive model for bloodstream infection in intensive care unit COVID-19 patients

Strelkova, D.; Rachina, S.; Fedina, L.; Vlasenko, A.; Tetevina, M.; Drogashevskaya, D.; Chesnokova, M.; Kuleshov, V.; Burmistrova, E.; Sychev, I.; Ananicheva, N.

doi:10.1016/j.jhin.2023.06.026

Cited by 3 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…tocilizumab or anakinra) and dexamethasone, among others. 78 Of interest, a high percentage (16/19; 84.2%) of patients with secondary infections/co-infections in our review received corticosteroids.…”

Section: Discussionmentioning

confidence: 91%

COVID-19 associated with cryptococcosis: a scoping review

Quincho-Lopez,

Poma,

José Montenegro-Idrogo

2024

Therapeutic Advances in Infection

View full text Add to dashboard Cite

Background: There is growing evidence of fungal infections associated with COVID-19. The development of cryptococcosis in these patients has been infrequently reported. However, it can be life-threatening. Objective: To identify cases of COVID-19 patients who developed cryptococcosis and to compare baseline characteristics and management between those who survived and those who died. Methods: We conducted a scoping review using PubMed, Scopus, Web of Science, and Embase to identify studies that reported patients with COVID-19 and cryptococcosis. No language restriction was applied. Single case reports, case series, and original articles were included. It is important to note that ‘ n’ refers to the total number of individuals with the specified variable. Results: A total of 58 studies were included. Among these studies, 51 included individual patient data, detailing information on a total of 65 patients, whereas eight studies reported the proportion of cryptococcosis in COVID-19 patients. One study provided both individual and aggregate case information. From individual patient data, the majority were male (73.9%; n = 48) with a median age of 60 years (range: 53–70). Severe COVID-19 and multiple comorbidities, led by arterial hypertension and diabetes mellitus, were frequently reported, but few had classic immunosuppression factors. On the other hand, HIV status, either negative or positive, was reported in just over half of the patients (61.5%; n = 40). Most were admitted to the intensive care unit (ICU) (58.5%; n = 31), received mechanical ventilation (MV) (50.0%; n = 26), and developed disseminated cryptococcosis (55.4%; n = 36). Secondary infection, mainly bacterial, was reported in 19 patients (29.2%). Mortality was 47.7% ( n = 31). Of the studies that reported the proportion of cryptococcosis in COVID-19 cases, the majority were descriptive studies published as conference abstracts. Conclusion: Cryptococcosis in COVID-19 patients has been reported more frequently. However, it is still not as common as other fungal infections associated with COVID-19. Few patients have some classic immunosuppression factors. The factors associated with mortality were male sex, age, ICU admission, MV, secondary infections, and lymphopenia.

show abstract

Section: Discussionmentioning

confidence: 91%

COVID-19 associated with cryptococcosis: a scoping review

Quincho-Lopez,

Poma,

José Montenegro-Idrogo

2024

Therapeutic Advances in Infection

View full text Add to dashboard Cite

show abstract

Bloodstream infections in the era of the COVID-19 pandemic: Changing epidemiology of antimicrobial resistance in the intensive care unit

Ntziora,

Giannitsioti

2024

Journal of Intensive Medicine

View full text Add to dashboard Cite

Bacterial co-infection in COVID-19: a call to stay vigilant

Liu,

Yu,

et al. 2024

PeerJ

View full text Add to dashboard Cite

Co-infection with diverse bacteria is commonly seen in patients infected with the novel coronavirus, SARS-CoV-2. This type of co-infection significantly impacts the occurrence and development of novel coronavirus infection. Bacterial co-pathogens are typically identified in the respiratory system and blood culture, which complicates the diagnosis, treatment, and prognosis of COVID-19, and even exacerbates the severity of disease symptoms and increases mortality rates. However, the status and impact of bacterial co-infections during the COVID-19 pandemic have not been properly studied. Recently, the amount of literature on the co-infection of SARS-CoV-2 and bacteria has gradually increased, enabling a comprehensive discussion on this type of co-infection. In this study, we focus on bacterial infections in the respiratory system and blood of patients with COVID-19 because these infection types significantly affect the severity and mortality of COVID-19. Furthermore, the progression of COVID-19 has markedly elevated the antimicrobial resistance among specific bacteria, such as Klebsiella pneumoniae, in clinical settings including intensive care units (ICUs). Grasping these resistance patterns is pivotal for the optimal utilization and stewardship of antibiotics, including fluoroquinolones. Our study offers insights into these aspects and serves as a fundamental basis for devising effective therapeutic strategies. We primarily sourced our articles from PubMed, ScienceDirect, Scopus, and Google Scholar. We queried these databases using specific search terms related to COVID-19 and its co-infections with bacteria or fungi, and selectively chose relevant articles for inclusion in our review.

show abstract

Identification of risk factors and development of a predictive model for bloodstream infection in intensive care unit COVID-19 patients

Cited by 3 publications

References 31 publications

COVID-19 associated with cryptococcosis: a scoping review

COVID-19 associated with cryptococcosis: a scoping review

Bloodstream infections in the era of the COVID-19 pandemic: Changing epidemiology of antimicrobial resistance in the intensive care unit

Bacterial co-infection in COVID-19: a call to stay vigilant

Contact Info

Product

Resources

About